Twitter Linkedin Instagram

Pipeline

Take a closer look at the progress of our first-in-class therapeutics for pruritus.

  • Phase 1
  • Phase 2
  • Phase 3
  • Approval

Commercial Rights

KORSUVA® Injection1

HD-CKD

  • Phase 1
  • Phase 2
  • Phase 3
  • Approval

Commercial Rights:

VFMCRP (ex-Japan and S. Korea)2,3

VFMCRP
(ex-Japan and
S. Korea)2,3

Oral difelikefalin

Advanced CKD
(stages IV-V)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approval

Commercial Rights:

Cara Therapeutics

Atopic Dermatitis

  • Phase 1
  • Phase 2
  • Phase 3
  • Approval

Commercial Rights:

Cara Therapeutics

Notalgia Paresthetica

  • Phase 1
  • Phase 2
  • Phase 3
  • Approval

Commercial Rights:

Cara Therapeutics

Footnotes:

  1. KORSUVA® is indicated for the treatment of moderate to severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Approved in the EU, UK and Switzerland with the tradename Kapruvia™. 
  2. Commercialization rights to difelikefalin in defined indications – Japan: Maruishi Pharmaceutical Co, LTD; South Korea: Chong Kun Dang Pharmaceuticals.
  3. Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has commercial rights under a profit-share arrangement in the US and a royalty arrangement ex-US.
    HD-CKD: Hemodialysis Chronic Kidney Disease; CKD: Chronic Kidney Disease